Abemaciclib, which demonstrates BBB penetration, is being examined for use as an ER+ endocrine resistance metastatic breast cancer treatment to specifically target CDK4/6 and inhibit cell proliferation [6, 77–79]. This evidence concerns the gene ESR1 and breast carcinoma.